Takeda Pharmaceutical (TAK) news

Takeda: Orzeiful Oveprexton launches in Japan, China

Takeda Pharmaceuticals has announced the approval and launch of Orzeyful (oveporexton) in China and Japan for the treatment of narcolepsy type 1, marking a significant milestone in the company’s portfolio of neurological therapies. Orzeyful, a first-in-class orexin OX2 receptor agonist, was…

Iambic Therapeutics - Prices IPO of 9,375,000 shares at $16 per share

Iambic Therapeutics (IAM), a San Diego-based biotechnology firm leveraging artificial intelligence in drug discovery, has priced its initial public offering (IPO) at $16 per share, raising $150 million in gross proceeds. The offering includes 9.375 million shares on the Nasdaq Global Select Market,…

Iambic announces pricing of initial public offering

Iambic Therapeutics Inc. has announced the pricing of its initial public offering (IPO), which it filed with the SEC . The San Diego-based biotechnology company, which leverages artificial intelligence for drug discovery, plans to list on Nasdaq . The IPO is expected to raise $159.4 million, with…

Takeda presents phase 2/3 Ignite study results of investigational subcutaneous TAK-881 in primary immunodeficiency disease (PID) at ESID 2026

Iambic Therapeutics - Ark investment and Duquesne family office indicate interest to purchase up to $60 mln in shares in IPO at IPO price

San Diego-based Iambic Therapeutics, a clinical-stage biotech firm leveraging AI for drug discovery, has filed for a $100 million IPO on the Nasdaq under the ticker "IAM". The company, backed by investors including Nvidia and the Qatar Investment Authority, is developing proprietary AI models with…